Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

Completed · Phase 1

Conditions studied: Rheumatoid Arthritis

In brief

The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).

Key facts

Study ID

NCT01262118

Run by

Pfizer

People needed

69

Starts

2011-05-01

Expected to finish

2012-02-01

Last updated by the study team

2013-01-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Males or females, 18 years of age or older with active rheumatoid arthritis; Or male and female healthy volunteers 18 years of age and older

You may not qualify if…

• Pregnant or lactating women
• Clinically significant systemic disease (other than RA for RA arm)
• Use of lipid-regulating agents

Where it is running

• Pfizer Investigational Site — Anniston, Alabama, United States
• Pfizer Investigational Site — Anniston, Alabama, United States
• Pfizer Investigational Site — Little Rock, Arkansas, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Daytona Beach, Florida, United States
• Pfizer Investigational Site — Ormond Beach, Florida, United States
• Pfizer Investigational Site — South Miami, Florida, United States
• Pfizer Investigational Site — Bingham Farms, Michigan, United States
• Pfizer Investigational Site — Dallas, Texas, United States
• Pfizer Investigational Site — Balatonfüred, Hungary
• Pfizer Investigational Site — Budapest, Hungary

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.